Lixte Biotechnology Holdings, Inc. LIXT 深 滬
等待開盤 06-15 09:30:00 美东时间
6.19
-1.060
-14.62%
華盛通- 最 高7.11
- 今 開7.11
- 成交量 87.18万股
- 最 低 5.875
- 昨 收 7.25
- 總市值 7665.04万
- 52周最高 7.51
- 市盈率 靜 --
- 換手率 7.04%
- 52周最低 0.677
- 委 比 39.92%
- 總股本 1238.29万
- 歷史最高 71.90
- 量 比 2.99
- 振 幅 17.03%
- 歷史最低 0.64
- 每 手 1
- 風險率 1.22%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多LIXTE Biotechnology To Seek Strategic Acquisition Partner For Its Clinical Stage Pharmaceutical And Med-Tech Business
LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), today announced its strategic transformation into an AI energy infrastructure equipment & services platform focused on meeting the rapidly
06-01 20:52
Lixte Biotech Hldgs Q1 EPS $(0.18) Up From $(0.29) YoY
Lixte Biotech Hldgs (NASDAQ:LIXT) reported quarterly losses of $(0.18) per share. This is a 37.93 percent increase over losses of $(0.29) per share from the same period last year.
05-15 05:17
Lixte Biotech Hldgs Q4 EPS $(0.34) Down From $(0.27) YoY
Lixte Biotech Hldgs (NASDAQ:LIXT) reported quarterly losses of $(0.34) per share. This is a 25.93 percent decrease over losses of $(0.27) per share from the same period last year.
04-01 06:52
LIXTE Biotechnology Holdings (NASDAQ: LIXT) Adds Innovative LiGHT Therapy to Pipeline
Austin, Texas, United States, March 10th, 2026, FinanceWire LIXTE Biotechnology...
03-11 00:00
LIXTE Announces An Expansion Of Its Collaboration With The University Of Texas MD Anderson Cancer Center And Pharmaceutical Manufacturer GSK On An Ongoing Clinical Trial Evaluating Its Proprietary Compound LB-100 In Combination With GSK's Dostarlimab For The Treatment Of Ovarian Clear Cell Cancer
LIXTE Biotechnology Holdings (NASDAQ:LIXT) announced an expansion of its collaboration with The University of Texas MD Anderson Cancer Center and pharmaceutical manufacturer GSK on an ongoing clinical trial
01-09 05:02
Lixte Biotechnology Enters Share Exchange Agreement, Swapping 2,700 Series C Preferred Shares For 700,000 Common Shares And ~20% Of Outstanding Shares For Subsidiary Liora Technologies Europe
On December 30, 2025, Lixte Biotechnology Holdings, Inc., a Delaware corporation (the "Company"), entered into a Share Exchange Agreement (the "Agreement") with Orbit Capital Inc., a Cayman Islands corporation
01-01 05:05
Lixte Biotechnology Announces New Registered Direct Offering
Lixte Biotechnology Holdings ( ($LIXT) ) has shared an announcement. On Decembe...
2025-12-23 06:48
Lixte Biotechnology Holdings shares are trading lower after the company announced it commenced a $4.3 million common stock offering at $4.09 per common unit.
Lixte Biotechnology Holdings shares are trading lower after the company announc...
2025-12-18 22:26
Lixte Biotechnology Commences $4.3M Common Stock, Pre-Funded Offering At $4.09/Common Unit
Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) (the "Company"), a biotech company focused on advancing cancer treatments, today announced that it has entered into definitive agreements in a registered direct offering
2025-12-18 22:11
Lixte Biotechnology Holds Annual Meeting, Approves Key Issues
The latest update is out from Lixte Biotechnology Holdings ( ($LIXT) ). On Dece...
2025-12-12 04:17
